Skip to main content
Discover what's not being covered
Get Started
SubscribeLogin
Published • loading... • Updated

ImmVira Presents Clinical Data from Three Bladder Cancer Studies at ESMO 2026

Summary by Floyd Chronicle & Times
SUZHOU, China, Oct. 22, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead oncolytic immunotherapy candidate, MVR-T3011, will be presented at the 2026 European Society for Medical Oncology (ESMO)…

31 Articles

The PennThe Penn
+30 Reposted by 30 other sources
Center

ImmVira Presents Clinical Data from Three Bladder Cancer Studies at ESMO 2026

SUZHOU, China, Oct. 22, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead oncolytic immunotherapy candidate, MVR-T3011, will be presented at the 2026 European Society for Medical Oncology (ESMO)…

·Indiana, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 84% of the sources are Center
84% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in Chicago, United States on Friday, October 23, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Suzhou, China icon

Suzhou, China

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal